Alacizumab pegol

From WikiMD's WELLNESSPEDIA

Alacizumab pegol

INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	934216-54-3
PubChem
DrugBank
ChemSpider	none
KEGG

Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')₂ fragment of a monoclonal antibody.^[1]

References[edit]

↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-osu-")	* Burosumab Denosumab
Humanized ("-sozu-")	* Blosozumab Romosozumab

Musculoskeletal ("-mul-")

Human ("-mulu-")

* Stamulumab^†

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Growth factor receptor modulators

* Agonists: Angiopoietin 1

Angiopoietin 4

Antagonists: Angiopoietin 2
Angiopoietin 3

Kinase inhibitors: Altiratinib
CE-245677
Rebastinib

Antibodies: Evinacumab (against angiopoietin 3)
Nesvacumab (against angiopoietin 2)

* Agonists: Axokine

EGF (ErbB1/HER1)	* Agonists: Amphiregulin Betacellulin EGF (urogastrone) Epigen Epiregulin Heparin-binding EGF-like growth factor (HB-EGF) Murodermin Nepidermin Transforming growth factor alpha (TGFα) Kinase inhibitors: Afatinib AG-490 Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab
ErbB2/HER2	* Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors: Afatinib AG-490 Lapatinib Mubritinib Neratinib Tucatinib
ErbB3/HER3	* Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies: Duligotumab Patritumab Seribantumab
ErbB4/HER4	* Agonists: Betacellulin Epigen Heparin-binding EGF-like growth factor (HB-EGF) Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))

FGFR1	* Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20) Repifermin Selpercatinib Trafermin Velafermin
FGFR2	* Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22) Palifermin Repifermin Selpercatinib Sprifermin Trafermin Antibodies: Aprutumab Aprutumab ixadotin
FGFR3	* Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23)
FGFR4	* Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8, 9, 19) Trafermin
FGFRL1 (FGFR5)

* Agonists: Hepatocyte growth factor

Potentiators: Dihexa (PNB-0408)

;See also

Receptor/signaling modulators

Signaling peptide/protein receptor modulators

Cytokine receptor modulators

This monoclonal antibody–related article is a stub. You can help WikiMD by expanding the page.

This medical article is a stub. You can help WikiMD by expanding the page.

Retrieved from "https://wikimd.org/index.php?title=Alacizumab_pegol&oldid=6532218"